Table 1: Tissue culture-based candidate biomarkers discovery in different cancers.

Cancer typesCell lines usedBiomarker identifiedClinical relevanceQuantitative techniques usedReference

Breast cancer21T series of Breast cancer cell lines 
HMT-3522-S1, MFM223, HCC202 and HCC2218, HCC1599, HCC1143, HCC1937, MCF7, MCF10A, MDA-MB-453
TIMM 17A 
IDH2, CRABP2, SEC14L2
Disease prognosis 
Disease progression and monitoring
SILAC and LC-MS/MS 
SILAC and MALDI-MS/MS
[5] 
[44]

Prostate cancerPC3, LnCAP, 22Rv1Follistatin, chemokine (C-X-C motif) ligand 16, Pentraxin 3, and spondin 2 Disease progression and monitoringTwo-dimensional chromatography and tandem mass spectrometry 
2D-DIGE, MALDI-MS/MS
[76] 
[92]

Lung cancer1198 and 1170-I, BEAS-2B and 1799 
CL1-0 and CL1-5
PGP9.5, TCTP, TIMP-2, and TPI 
KPNA2
Disease monitoring 
Disease detection and progression monitoring
2DE and MS 
SILAC, LC-MS/MS
[81] 
[46]

Gastric cancer
AGS and MKN7
GRN
Disease detection and monitoring2D-LC-MS/MS and iTRAQ[93]

Pancreatic cancerPANC1, BxPc3, MIA-PaCa2, SU.86.86Anterior gradient homolog 2, syncollin, olfactomedin-4, polymeric immunoglobulin
receptor, and collagen alpha-1(VI) chain
Early disease detection and monitoringLC-MS/MS, ELISA[94]

Colorectal cancerTumor samples were cultured in vitro EFEMP2Detection and monitoring1D-LC-MS/MS[95]

Head and Neck cancerSCC4, HSC2, SCC38, and AMOSIIIalpha-enolase, peptidyl prolyl isomerase A/cyclophilin A, 14-3-3 z, heterogeneous ribonucleoprotein K, and 14-3-3 sDisease detection and progression monitoringLC-MS/MS, western blot[96]

Oral cancerOEC-M1 and SCC4 
OEC-M1 and SCC4
Mac-2 BP 
Guanylate-binding protein 1 (GBP1)
Early detection of disease 
Disease detection and progression
MALDI-TOF MS 
1D and LC-MS/MS
[97] 
[98]

Renal cell carcinoma786-O, Caki-1, A498, ACHN OS-RC-2, HK-2, HUVECFoxM1Detection and potential drug targetIHC, western blot, ELISA[99]